US equities |
MU $1,035.84 ▲+0.00% SPCX $160.57 ▲+0.00% NVDA $230.48 ▲+0.00% AAPL $340.42 ▲+0.00% SNDK $1,609.46 ▲+0.00% INTC $107.08 ▲+0.00% AMD $620.68 ▲+0.00% LITE $1,048.60 ▲+0.00%
FinancialContent

Equillium, Inc. - Common Stock (NQ:EQ)

1.440 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗
 
Via Benzinga
News headline image
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients ↗
Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on potential Accelerated Approval is expected in May. 
Via Benzinga
News headline image
Top movers in Thursday's pre-market session ↗
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
News headline image
Which stocks are moving on Thursday? ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Stifel Healthcare Conference
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Equillium Maintains Rights to Itolizumab Following Ono Partnership
From Equillium Inc.
Via Business Wire
News headline image
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
News headline image
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024 ↗
EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
From Equillium Inc.
Via Business Wire
News headline image
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Participate in Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to be included in the Russell Microcap® Index
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
News headline image
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >